ATE428423T1 - Aripiprazol-komplex-formulierung und verfahren - Google Patents

Aripiprazol-komplex-formulierung und verfahren

Info

Publication number: ATE428423T1
Authority: AT; Austria
Prior art keywords: methods; complex formulation; aripiprazole; aripiprazole complex; formulation
Prior art date: 2002-08-20

Application number

AT03751859T

Other languages

English (en)

Inventor

Manoj Nerurkar

Vijay Naringrekar

Mark Dominick

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-20

Filing date

2003-08-14

Publication date

2009-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31946748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE428423(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-08-14 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2009-05-15 Application granted granted Critical

2009-05-15 Publication of ATE428423T1 publication Critical patent/ATE428423T1/de

Links

CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title 1
229960004372 aripiprazole Drugs 0.000 title 1
238000009472 formulation Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nanotechnology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Biotechnology (AREA)
Inorganic Chemistry (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT03751859T 2002-08-20 2003-08-14 Aripiprazol-komplex-formulierung und verfahren ATE428423T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40471302P	2002-08-20	2002-08-20
PCT/US2003/025573 WO2004017897A2 (en)	2002-08-20	2003-08-14	Aripiprazole complex formulation and method

Publications (1)

Publication Number	Publication Date
ATE428423T1 true ATE428423T1 (de)	2009-05-15

Family

ID=31946748

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03751859T ATE428423T1 (de)	2002-08-20	2003-08-14	Aripiprazol-komplex-formulierung und verfahren

Country Status (32)

Country	Link
US (8)	US7115587B2 (de)
EP (1)	EP1542668B1 (de)
JP (1)	JP4729306B2 (de)
KR (1)	KR101043866B1 (de)
CN (1)	CN100335047C (de)
AR (2)	AR040887A1 (de)
AT (1)	ATE428423T1 (de)
AU (1)	AU2003269965B2 (de)
BR (1)	BR0313602A (de)
CA (1)	CA2495864C (de)
CY (1)	CY1110331T1 (de)
DE (1)	DE60327225D1 (de)
DK (1)	DK1542668T3 (de)
ES (1)	ES2322953T3 (de)
GE (1)	GEP20063996B (de)
HR (1)	HRP20050149B1 (de)
IL (1)	IL166623A (de)
IS (1)	IS2878B (de)
MX (1)	MXPA05001865A (de)
MY (1)	MY140793A (de)
NO (1)	NO333458B1 (de)
NZ (1)	NZ537995A (de)
PE (1)	PE20040895A1 (de)
PL (1)	PL212428B1 (de)
PT (1)	PT1542668E (de)
RS (1)	RS51903B (de)
RU (1)	RU2342931C2 (de)
SI (1)	SI1542668T1 (de)
TW (1)	TWI307626B (de)
UA (1)	UA79984C2 (de)
WO (1)	WO2004017897A2 (de)
ZA (1)	ZA200501064B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040170705A1 (en) *	2001-03-08	2004-09-02	Dusan Miljkovic	Compositions and methods for non-insulin glucose uptake
CA2495864C (en) *	2002-08-20	2011-09-27	Bristol-Myers Squibb Company	Aripiprazole complex formulation and method
ATE411797T2 (de) *	2003-10-23	2008-11-15	Otsuka Pharma Co Ltd	Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
CA2550726A1 (en) *	2003-12-16	2005-06-30	Teva Pharmaceutical Industries Ltd.	Methods of preparing aripiprazole crystalline forms
US7714129B2 (en)	2003-12-16	2010-05-11	Teva Pharmaceutical Industries Ltd.	Methods of preparing anhydrous aripiprazole form II
UA89513C2 (uk) *	2004-12-03	2010-02-10	Элан Фарма Интернешнл Лтд.	Стабільна композиція з наночастинок ралоксифену гідрохлориду
GB2442366A (en) *	2005-04-13	2008-04-02	Elan Pharma Int Ltd	Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
ES2341996T3 (es) *	2005-06-03	2010-06-30	Elan Pharma International Limited	Formulaciones de mesilato de imatinib en forma de manoparticulas.
US20090036406A1 (en) *	2005-06-13	2009-02-05	Takeda Pharmaceutical Company Limited	Injection
US20100204178A1 (en)	2006-10-02	2010-08-12	James Cloyd	Novel parenteral carbamazepine formulation
CN101583620B (zh)	2005-11-28	2016-08-17	马里纳斯医药公司	加奈索酮组合物及其制备和使用方法
GB0618879D0 (en)	2006-09-26	2006-11-01	Zysis Ltd	Pharmaceutical compositions
CN101322709B (zh) *	2007-06-12	2011-03-02	成都康弘药业集团股份有限公司	一种含有阿立哌唑的药物组合物及其制备方法
MY152789A (en) *	2007-07-31	2014-11-28	Otsuka Pharma Co Ltd	Methods for producing aripiprazole suspension and freeze-dried formulation
WO2009048947A1 (en) *	2007-10-09	2009-04-16	Board Of Regents, The University Of Texas System	Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors
MX2010009848A (es) *	2008-03-21	2010-09-30	Elan Pharma Int Ltd	Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
US7635773B2 (en)	2008-04-28	2009-12-22	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions
LT2445502T (lt)	2009-06-25	2017-09-25	Alkermes Pharma Ireland Limited	Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
CA2937222C (en)	2009-06-25	2019-06-04	Alkermes Pharma Ireland Limited	Prodrugs of nh-acidic compounds
WO2011023796A1 (en)	2009-08-31	2011-03-03	Abbott Healthcare Products B.V.	Bifeprunox for treating addiction
KR101125210B1 (ko) *	2009-09-11	2012-03-19	주식회사 대웅제약	아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
US20110140304A1 (en) *	2009-12-10	2011-06-16	Molecular Imprints, Inc.	Imprint lithography template
AU2011270701B2 (en)	2010-06-24	2015-05-14	Alkermes Pharma Ireland Limited	Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US8383663B2 (en) *	2010-07-19	2013-02-26	Supratek Pharma Inc.	Bendamustine anionic-catioinic cyclopolysaccharide compositions
BR112013023847B1 (pt)	2011-03-18	2021-02-23	Alkermes Pharma Ireland Limited	composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas
NZ722096A (en)	2011-12-15	2016-11-25	Alkermes Pharma Ireland Ltd	Prodrugs of secondary amine compounds
TW201332572A (zh) *	2011-12-28	2013-08-16	Otsuka Pharma Co Ltd	具有經取代的β－環糊精之藥物製劑
DK3702374T3 (da)	2012-02-15	2022-06-27	Cydex Pharmaceuticals Inc	Fremsgangsmåde til fremstilling for cyclodextrin-derivater
AU2013235523B9 (en)	2012-03-19	2018-01-04	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising glycerol esters
AU2013235526B2 (en)	2012-03-19	2017-11-30	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising benzyl alcohol
CA2867121C (en)	2012-03-19	2021-05-25	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising fatty acid esters
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
KR101571670B1 (ko)	2012-08-08	2015-11-25	주식회사 씨엠지제약	아리피프라졸을 포함하는 경구용 속용 필름 제제
JP6654042B2 (ja)	2012-09-19	2020-02-26	アルカームスファーマアイルランドリミテッド	貯蔵安定性が改善された医薬組成物
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
GR1008186B (el)	2013-04-22	2014-05-08	"Φαρματεν Α.Β.Ε.Ε.",	Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
JP6203682B2 (ja) *	2013-07-10	2017-09-27	共和薬品工業株式会社	アリピプラゾール含有水性液剤
US10525057B2 (en)	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150086408A1 (en) *	2013-09-26	2015-03-26	General Electric Company	Method of manufacturing a component and thermal management process
PL3639828T3 (pl)	2013-12-24	2022-05-02	Virginia Commonwealth University	Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
GR1008442B (el)	2014-01-16	2015-03-05	"Φαρματεν Α.Β.Ε.Ε.",	Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
CN106132415A (zh)	2014-03-20	2016-11-16	奥克梅斯制药爱尔兰有限公司	具有增加的注射速度的阿立哌唑制剂
CN105078910B (zh) *	2015-09-22	2018-05-22	成都欣捷高新技术开发有限公司	一种含有依匹哌唑的冻干口服制剂及其制备方法
EA036155B1 (ru)	2015-10-16	2020-10-06	Маринус Фармасьютикалс, Инк.	Инъекционные составы нейростероида, содержащие наночастицы
CN105616344A (zh) *	2016-01-06	2016-06-01	万全万特制药江苏有限公司	阿立哌唑注射液及其制备方法
EP3494125B1 (de) *	2016-08-02	2022-06-22	Virginia Commonwealth University	Zusammensetzungen mit 5-cholesten-3, 25-diol, 3-sulfat (25hc3s) oder ein pharmazeutisch akzeptables salz davon und mindestens ein cyclisches oligosaccharid
EP4233861A3 (de)	2016-08-11	2023-10-11	Ovid Therapeutics, Inc.	Zusammensetzungen zur behandlung von essentiellem tremor
US10391105B2 (en)	2016-09-09	2019-08-27	Marinus Pharmaceuticals Inc.	Methods of treating certain depressive disorders and delirium tremens
TW201828938A (zh)	2016-11-18	2018-08-16	德商艾庫里斯抗感染治療有限公司	以改質的環糊精及酸化劑為基底之經脒取代之β-內醯胺化合物的新穎調配物，其製備方法及作為抗微生物醫藥組合物之用途
WO2019102992A1 (ja) *	2017-11-21	2019-05-31	積水化学工業株式会社	皮膚外用剤
EP3761983A1 (de)	2018-03-05	2021-01-13	Alkermes Pharma Ireland Limited	Dosierstrategie für aripiprazol
US11266662B2 (en)	2018-12-07	2022-03-08	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in prophylaxis and treatment of postpartum depression
CN114728012A (zh)	2019-08-05	2022-07-08	马瑞纳斯制药公司	用于治疗癫痫持续状态的加奈索酮
JP7780431B2 (ja)	2019-12-06	2025-12-04	マリナスファーマシューティカルズ，インコーポレイテッド	結節性硬化症の治療での使用のためのガナキソロン
JP2023551145A (ja) *	2020-11-18	2023-12-07	ベクソンバイオメディカル，インク．	医薬化合物の錯化剤塩製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6407079B1 (en)	1985-07-03	2002-06-18	Janssen Pharmaceutica N.V.	Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en)	1987-12-30	1991-03-26	University Of Florida	Improvements in redox systems for brain-targeted drug delivery
US5006528A (en)	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
JP2893175B2 (ja) *	1988-10-31	1999-05-17	大塚製薬株式会社	カルボスチリル誘導体
JP2608788B2 (ja) *	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1263831B (it)	1993-01-29	1996-09-04	Paolo Chiesi	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
JPH07165616A (ja) *	1993-12-09	1995-06-27	Hisamitsu Pharmaceut Co Inc	シクロデキストリンの複合組成物及び複合化法
US5646131A (en)	1994-02-22	1997-07-08	The Arab Company For Drug Industries And Medical Applicances (Acdima)	Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it)	1994-04-22	1997-04-08	Chiesi Farma Spa	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
UA57734C2 (uk)	1996-05-07	2003-07-15	Пфайзер Інк.	Комплекси включення арилгетероциклічних солей
JP4012994B2 (ja)	1996-05-08	2007-11-28	大塚製薬株式会社	抗不安薬
JPH10194996A (ja)	1996-12-25	1998-07-28	Janssen Pharmaceut Nv	アシル化シクロデキストリン含有製薬組成物
GB9713149D0 (en)	1997-06-21	1997-08-27	Pfizer Ltd	Pharmaceutical formulations
GB9915231D0 (en)	1999-06-29	1999-09-01	Pfizer Ltd	Pharmaceutical complex
CA2311734C (en)	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Flash-melt oral dosage formulation
MY129350A (en) *	2001-04-25	2007-03-30	Bristol Myers Squibb Co	Aripiprazole oral solution
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
SE0200301D0 (sv) *	2002-02-01	2002-02-01	Axon Biochemicals Bv	Thio-carbostyril derivative
CA2495864C (en) *	2002-08-20	2011-09-27	Bristol-Myers Squibb Company	Aripiprazole complex formulation and method
JP2006505579A (ja)	2002-10-25	2006-02-16	ファイザー・プロダクツ・インク	懸濁形態でのアリール複素環活性薬物の蓄積製剤

2003
- 2003-08-14 CA CA2495864A patent/CA2495864C/en not_active Expired - Fee Related
- 2003-08-14 RU RU2005107471/15A patent/RU2342931C2/ru not_active IP Right Cessation
- 2003-08-14 PT PT03751859T patent/PT1542668E/pt unknown
- 2003-08-14 NZ NZ537995A patent/NZ537995A/en not_active IP Right Cessation
- 2003-08-14 DE DE60327225T patent/DE60327225D1/de not_active Expired - Lifetime
- 2003-08-14 PL PL374798A patent/PL212428B1/pl unknown
- 2003-08-14 CN CNB038195534A patent/CN100335047C/zh not_active Expired - Fee Related
- 2003-08-14 DK DK03751859T patent/DK1542668T3/da active
- 2003-08-14 JP JP2004531017A patent/JP4729306B2/ja not_active Expired - Fee Related
- 2003-08-14 GE GEAP8703A patent/GEP20063996B/en unknown
- 2003-08-14 US US10/642,366 patent/US7115587B2/en not_active Expired - Lifetime
- 2003-08-14 AU AU2003269965A patent/AU2003269965B2/en not_active Ceased
- 2003-08-14 KR KR1020057002789A patent/KR101043866B1/ko not_active Expired - Fee Related
- 2003-08-14 SI SI200331586T patent/SI1542668T1/sl unknown
- 2003-08-14 MX MXPA05001865A patent/MXPA05001865A/es active IP Right Grant
- 2003-08-14 RS YU20050118A patent/RS51903B/sr unknown
- 2003-08-14 WO PCT/US2003/025573 patent/WO2004017897A2/en not_active Ceased
- 2003-08-14 TW TW092122407A patent/TWI307626B/zh not_active IP Right Cessation
- 2003-08-14 HR HRP20050149AA patent/HRP20050149B1/hr not_active IP Right Cessation
- 2003-08-14 EP EP03751859A patent/EP1542668B1/de not_active Expired - Lifetime
- 2003-08-14 ES ES03751859T patent/ES2322953T3/es not_active Expired - Lifetime
- 2003-08-14 UA UAA200502492A patent/UA79984C2/uk unknown
- 2003-08-14 BR BR0313602-7A patent/BR0313602A/pt not_active Application Discontinuation
- 2003-08-14 AT AT03751859T patent/ATE428423T1/de active
- 2003-08-15 MY MYPI20033103A patent/MY140793A/en unknown
- 2003-08-19 AR AR20030102990A patent/AR040887A1/es not_active Application Discontinuation
- 2003-08-20 PE PE2003000843A patent/PE20040895A1/es not_active Application Discontinuation
2005
- 2005-02-01 IL IL166623A patent/IL166623A/en active IP Right Grant
- 2005-02-04 ZA ZA200501064A patent/ZA200501064B/xx unknown
- 2005-02-08 NO NO20050661A patent/NO333458B1/no not_active IP Right Cessation
- 2005-02-18 IS IS7701A patent/IS2878B/is unknown
2006
- 2006-06-14 US US11/452,782 patent/US7550445B2/en not_active Expired - Fee Related
2009
- 2009-04-02 US US12/417,067 patent/US20090186903A1/en not_active Abandoned
- 2009-07-07 CY CY20091100712T patent/CY1110331T1/el unknown
2011
- 2011-03-11 US US13/046,124 patent/US20110160224A1/en not_active Abandoned
- 2011-11-03 US US13/288,077 patent/US20120053145A1/en not_active Abandoned
2012
- 2012-10-22 US US13/656,785 patent/US20130045981A1/en not_active Abandoned
2013
- 2013-04-29 US US13/872,517 patent/US8999952B2/en not_active Expired - Fee Related
2015
- 2015-03-03 US US14/636,283 patent/US20150328335A1/en not_active Abandoned
- 2015-09-28 AR ARP150103114A patent/AR102101A2/es unknown

Also Published As

Publication number	Publication date
NO333458B1 (no)	2013-06-10
PL212428B1 (pl)	2012-09-28
PT1542668E (pt)	2009-06-09
US7115587B2 (en)	2006-10-03
AU2003269965A1 (en)	2004-03-11
KR20050040927A (ko)	2005-05-03
AR040887A1 (es)	2005-04-20
IS7701A (is)	2005-02-18
CA2495864C (en)	2011-09-27
WO2004017897A2 (en)	2004-03-04
JP4729306B2 (ja)	2011-07-20
CA2495864A1 (en)	2004-03-04
US20090186903A1 (en)	2009-07-23
NO20050661L (no)	2005-03-16
GEP20063996B (en)	2006-12-11
SI1542668T1 (sl)	2009-08-31
EP1542668B1 (de)	2009-04-15
TW200405813A (en)	2004-04-16
US20140235574A1 (en)	2014-08-21
RU2342931C2 (ru)	2009-01-10
RS51903B (sr)	2012-02-29
US20110160224A1 (en)	2011-06-30
AR102101A2 (es)	2017-02-01
RS20050118A (sr)	2007-06-04
US7550445B2 (en)	2009-06-23
AU2003269965B2 (en)	2008-02-21
KR101043866B1 (ko)	2011-06-22
CN1674882A (zh)	2005-09-28
US20040077594A1 (en)	2004-04-22
CY1110331T1 (el)	2015-01-14
PL374798A1 (en)	2005-10-31
TWI307626B (en)	2009-03-21
DK1542668T3 (da)	2009-07-20
US20130045981A1 (en)	2013-02-21
EP1542668A2 (de)	2005-06-22
IL166623A (en)	2011-07-31
EP1542668A4 (de)	2007-10-17
US20120053145A1 (en)	2012-03-01
MY140793A (en)	2010-01-15
DE60327225D1 (de)	2009-05-28
HRP20050149B1 (hr)	2014-09-12
ZA200501064B (en)	2006-12-27
PE20040895A1 (es)	2004-11-20
IL166623A0 (en)	2006-01-15
HRP20050149A2 (en)	2005-10-31
UA79984C2 (en)	2007-08-10
CN100335047C (zh)	2007-09-05
MXPA05001865A (es)	2005-06-03
US20060234979A1 (en)	2006-10-19
RU2005107471A (ru)	2005-09-10
US20150328335A1 (en)	2015-11-19
NZ537995A (en)	2007-11-30
IS2878B (is)	2014-04-15
US8999952B2 (en)	2015-04-07
JP2006501240A (ja)	2006-01-12
ES2322953T3 (es)	2009-07-02
WO2004017897A3 (en)	2004-12-02
BR0313602A (pt)	2005-06-21

Legal Events

Date

Code

Title

Description

2009-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1542668

Country of ref document: EP

Publication	Publication Date	Title
ATE428423T1 (de)	2009-05-15	Aripiprazol-komplex-formulierung und verfahren
DE602005015421D1 (de)	2009-08-27	Direktkomprimierte formulierung und verfahren
DE602004006981D1 (de)	2007-07-26	Datenabrufende und -übertragende vorrichtungen und verfahren
DE602004017342D1 (de)	2008-12-04	Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
EP1504429A4 (de)	2006-05-03	Verfolgungssystem und zugeordnetes verfahren
DE60212580D1 (de)	2006-08-03	Ortungssystem und Verfahren
DE602004015326D1 (de)	2008-09-04	Schutz-bus-schnittstelle und verfahren
CY2014033I2 (el)	2016-04-13	Παραγωγα κινολινης και η χρηση τους ως μυκοβακτηριακων αναστολεων
DE60307766D1 (de)	2006-10-05	Gewürzmittel und Verfahren zu seiner Herstellung
DE60331729D1 (de)	2010-04-29	Audiocodierungsverfahren und audiocodierungseinrichtung
DE60208700D1 (de)	2006-04-06	Schälgerät und zugehörige verfahren
DE60333155D1 (de)	2010-08-12	Simultandolmetschen- System und Verfahren
DE60330080D1 (de)	2009-12-31	Pin Halterung und Verfahren
DE60309411D1 (de)	2006-12-14	Pollensensor und Verfahren
EP1599904A4 (de)	2006-04-26	Laterale lubistorstruktur und verfahren
DE60336039D1 (de)	2011-03-31	Verstellbares Bohrgerät und assoziiertes Verfahren
DE60320625D1 (de)	2008-06-12	Röntgenvorrichtung und Verfahren
EP1455841A4 (de)	2004-12-08	Osteopontin-verwandte zusammensetzungen und verfahren
DE602004027703D1 (de)	2010-07-29	Schwefelfreie zusammensetzung und schmiermittelzusammensetzung und verfahren davon
EP1740120A4 (de)	2008-06-25	Langzeitformulierungen von naltrexon und anwendungsverfahren
DE60317443D1 (de)	2007-12-27	H-Brückenvorrichtung und Verfahren
ATE459726T1 (de)	2010-03-15	Verfahren und produkte
DE60327836D1 (de)	2009-07-16	PVD-Vorrichtung und Verfahren
ATE418339T1 (de)	2009-01-15	Zusammensetzung und verfahren
DE60329227D1 (de)	2009-10-22	Bilderzeugungsvorrichtung und verfahren